Bob Hutchens, CEO of StemBioSys, Inc., developers of advanced stem cell technologies discusses research, which was recently published in peer-reviewed journal “Nature Scientific Reports” (Nov 2020), that demonstrates that CELLvo™ Matrix Plus, a jointly developed platform with Cartox, Inc., enables the widescale testing of experimental drugs via human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) and enables maturation in seven days compared to the current partial hiPSC-CM maturation within 30 to 100 days. Matrix Plus offers the potential to significantly reduce (and one day eliminate) the need to sacrifice animals for preclinical safety studies.
Robert (Bob) Hutchens, Chief Executive Officer, StemBioSys, Inc. Bob is a retired Partner of Booz & Company in New York. Booz & Company is a billion dollar management consulting firm with over 70 offices worldwide. Prior to Booz & Company Bob was a partner with the Management consulting firm of A.T. Kearney in New York.Bob has over 20 years of experience in management consulting. Most of his work has been with clients in the Life Sciences industry. His clients also included a number of major pharmaceutical companies as well as a range of medical device and supply companies.Bob also worked extensively with Centers for Disease Control (CDC) in Atlanta to redesign the supply chain and financial processes for the agency’s $4 billion Vaccine For Children (VFC) program. Additionally, Bob worked with the President’s Emergency Program For Aids Relief (PEPFAR) as well as with the Global Fund.Bob’s work with his clients addressed a range of topics including defining corporate strategies, developing market entry and launch strategies as well as working with these clients to improve the overall effectiveness of their organizations and operations. Bob holds a Bachelor of Business Administration from the Ross School of Business at The University of Michigan and he holds a Master of Business Administration from the Wharton School at the University of Pennsylvania.